📢 Study Highlights: PSA Decline as a Predictor in mHSPC Treatment
A retrospective multicenter study analyzed 633 patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide (2018-2023). PSA response at 3 months was strongly linked to outcomes:
✅ Complete Response (PSA ≤0.02 ng/ml): 27% of patients, 92% radiologic progression-free survival (rPFS) at 24 months.
⚠️ Partial Response (PSA >0.02-0.2 ng/ml): 42% of patients, 86% rPFS at 24 months.
❌ Incomplete Response (PSA >0.2 ng/ml): 31% of patients, 63% rPFS at 24 months, with nearly 50% progressing within 2 years.
🔑 Predictive factors for a complete PSA response:
•Use of next-generation imaging.
•PSA <50 ng/ml at diagnosis.
💡 Implications: Early PSA response after 3 months of treatment provides a powerful prognostic tool to guide therapy for mHSPC. Heterogeneity among patients and data quality remain key limitations
https://t.co/sbBVvBNwAK
“✏️Manejo del #cancertesticular en #LATAM “Tú participación es Importante . Oficina de 🔬 @CAU_URO @ResidentesCAU Dr.Raimundo Rodriguez 🇨🇱 . Te llevará solo 5 min ⏱ 👇👇 https://t.co/u9hUSQ6Psd
Gobierno de Chile considera q Jerusalén es ciudad con un status especial según ONU, y no reconoce la ocupación ilegal de Israel sobre Jerusalem Este. La decisión de EEUU obstaculiza y hace aún más difícil proceso de paz conducente a dos Estados.